The outlook for peptide drugs and the intricate relationship between the Active Pharmaceutical Ingredients manufacturer and their sponsors.

As research laboratories discover an ever-increasing number of peptides of pharmacological interest, there is an increased need for Good Manufacturing Practices (GMP) services, as these drugs candidates undergo clinical trials. It is therefore essential to understand the importance of the relationship with the Active Pharmaceutical Ingredients (API) manufacturer and its implications in the development and commercialization of the future peptide drug.